Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide | MicrobiomeTrials
Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide
RecruitingEARLY_PHASE1INTERVENTIONAL
Trial Details
Start: 2019-10-28Est. Completion: 2034-06-15
Enrollment target: 4 participants
Locations
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Other microbiome trials you might be interested in